The aim of this project is to validate an international brief instrument with open-ended responses that can be used alongside the EORTC QLQ-C15-PAL and the EORTC QLQ-C30 questionnaires. This instrument named ‘Write In three Symptoms/Problems’ (WISP), allows patients to report up to three symptoms and problems not covered by the EORTC questionnaires. It was developed in Denmark and has been used successfully for symptom assessment of patients in palliative care since 2010.
Following the pilot testing of the WISP translations, the new WISP instrument will be tested alongside EORTC questionnaires in cancer patients receiving curative and palliative treatment. Furthermore, we will develop an EORTC guideline for the use of this instrument and how to analyze its results.
– The grant contract has been signed in January 2022 and we are awaiting the closing of the data processing agreements made with the seven countries involved in the project.
– We have finished the Danish-English translation of WISP and started with the other translations.
– The project protocol and informed consent have been submitted for review and further ethical approval to all participating countries.
We are currently completing the translations of the WISP instrument to start the pilot testing in each country involved in the project (Phase III).
We anticipate completing Phase III of this project by April to September 2022.
The EORTC Quality of Life Group has developed several questionnaires to assess the perspective of cancer patients on their own symptomatology. However, static questionnaires with closed-ended responses can never cover all possible symptoms and problems experienced by these patients. Therefore, to improve the comprehensiveness of symptom assessment in cancer patients, this project aims to validate a short instrument with open-ended responses that permits patients to report up to three additional symptoms not included in the EORTC questionnaire they have completed. The results from this project will help doctors to understand the symptomatology of the disease and improve the treatment for cancer patients in the future.